Clovis Oncology Announces Data Presentations At 2016 ASCO Annual Meeting

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) today announced its presence at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, where it will share updated results from clinical studies of rucaparib. ASCO will take place June 3-7, 2016 in Chicago.

“We look forward to providing updates on rucaparib data in ovarian cancer, including in patients with mutations beyond BRCA, as well as the first presentation of our pancreatic cancer data,” said Patrick J. Mahaffy, CEO and President of Clovis Oncology.
MORE ON THIS TOPIC